Impact of Body Mass Index on Treatment Efficacy of Mirabegron for Overactive Bladder in Female

Abstrakt

Overactive bladder (OAB) is a debilitating condition affecting quality of life of many patients. Metabolic syndrome and obesity have been considered to be a risk factors for urinary incontinence and OAB.

The conclusive data comparing the treatment efficacy of OAB pharmacotherapy in normal weight versus obese patient population are not available. In this study we hypothesize that obesity would negatively impact the efficacy of the medical treatment of OAB with mirabegron.

Objective: To evaluate the impact of Body Mass Index (BMI) on treatment efficacy of mirabegron for OAB in adult female patients.